SGLT2抑制剂与糖尿病肾病的研究进展

Research progress of diabetic nephropathy and SGLT2 inhibitors

摘要:

钠-葡萄糖协同转运蛋白2（Sodium-glucose co-transport 2，SGLT2）抑制剂以其独特的作用机制成为近年来糖尿病研究的新热点。其不仅具有降低血糖及糖化血红蛋白的作用，还有其他附加效应，如减轻体质量，降低血压、血脂，改善胰岛素抵抗等，提示其可能对糖尿病肾病有直接或间接保护效应。相比目前糖尿病肾病经典治疗方法———肾素-血管紧张素-醛固酮系统阻断，不少动物实验表明SGLT2 抑制剂可改善肾结局指标，维持稳定的肾功能并减少尿蛋白。由此，SGLT2抑制剂有望改善糖尿病肾病的远期结局，成为糖尿病肾病的治疗选择。

Abstract:

In recent years，sodium-glucose co-transport 2（SGLT2） inhibitors become a hot topic in diabetes mellitus research be－cause of their unique mechanism. SGLT2 inhibitors not only function on controlling plasma glucose level and HbA1c，but also have some extra therapeutic benefits，for example，reducing the body weight，lowering blood pressure and serum lipids，improving insulin resistance，etc.，indicating a potential protective action on diabetic nephropathy. Compared with the blockade of the RAAS，a classic therapy for diabetic nephropathy in recent years，SGLT2 inhibitors may ameliorate renal end points，leading to a sustainable renal function and a decrease in albuminuria. Thus，SGLT2 inhibitors may be used to improve the long-term outcomes of diabetic nephro-pathy，and grows to be a therapy for diabetic nephropathy.